Search results
Systemic glucocorticosteroids are the drug of first choice in the treatment of sarcoidosis. Once started, there is a >50% chance of long-term treatment. Prolonged use of prednisone at >10 mg/day or equivalent is not advised due to frequent severe side effects.
- Treatment of Sarcoidosis: A Multidisciplinary Approach - PMC
The basis of treatment of sarcoidosis is regulation of the...
- Pulmonary sarcoidosis: A comprehensive review: Past to present
First line treatment for patients who are symptomatic (cough...
- Treatment of Sarcoidosis: A Multidisciplinary Approach - PMC
The basis of treatment of sarcoidosis is regulation of the heightened immune response and suppression of granulomatous inflammation in order to prevent dangerous interference with organ function (as seen in the eye or the heart) and to prevent eventual scarring and fibrosis as seen in the lungs.
29 lis 2022 · Sarcoidosis is a heterogeneous disease with variable organ involvement, disease course, and response to treatment. We offer an angle on when and how to treat, and provide an overall roadmap for managing sarcoidosis. Similar content being viewed by others. Introduction. Sarcoidosis is a very old disease.
The study evaluates the comparative efficacy of non-corticosteroid pharmacological interventions in improving pulmonary outcomes among patients with sarcoidosis. METHODS: We conducted a systematic review and network meta-analysis, identifying randomized controlled trials (RCTs) on pulmonary outcomes in sarcoidosis patients from PubMed, Embase ...
Sarcoidosis is the commonest interstitial lung disease (ILD), differing from most other ILDs in that many patients remain asymptomatic or improve spontaneously. Careful baseline assessment of disease distribution and severity is thus central to initial management.
18 lut 2019 · Key messages. This study provides detailed information on how the first set of patient-centred outcomes in patients with a diagnosis of pulmonary sarcoidosis was developed. The international process resulted in a consensus-driven recommended set.
19 paź 2023 · First line treatment for patients who are symptomatic (cough and dyspnea) with parenchymal infiltrates and abnormal pulmonary function testing (PFT) is oral glucocorticoids, such as prednisone with a typical starting dose of 20-40 mg daily for 2 weeks to 2 months.
